Last reviewed · How we verify
erythropoietin and early iron supplements
erythropoietin and early iron supplements is a Small molecule drug developed by Sheba Medical Center. It is currently in Phase 2 development.
At a glance
| Generic name | erythropoietin and early iron supplements |
|---|---|
| Sponsor | Sheba Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Early Short-term Intravenous Iron Supplements Combined EPO in Preterm Infants (PHASE4)
- Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- erythropoietin and early iron supplements CI brief — competitive landscape report
- erythropoietin and early iron supplements updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI
Frequently asked questions about erythropoietin and early iron supplements
What is erythropoietin and early iron supplements?
erythropoietin and early iron supplements is a Small molecule drug developed by Sheba Medical Center.
Who makes erythropoietin and early iron supplements?
erythropoietin and early iron supplements is developed by Sheba Medical Center (see full Sheba Medical Center pipeline at /company/sheba-medical-center).
What development phase is erythropoietin and early iron supplements in?
erythropoietin and early iron supplements is in Phase 2.
Related
- Manufacturer: Sheba Medical Center — full pipeline